-
Company Insights
Innovation and Patenting activity of Enzychem Lifesciences Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Enzychem Lifesciences Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Asthma Drug Details: Mosedipimod (EC-18) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Rheumatoid Arthritis Drug Details: Mosedipimod (EC-18) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Atopic Dermatitis (Atopic Eczema) Drug Details: Mosedipimod (EC-18)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Chemotherapy Induced Oral Mucositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Chemotherapy Induced Oral Mucositis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Chemotherapy Induced Oral Mucositis Drug Details: Mosedipimod (EC-18)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Mosedipimod (EC-18)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute...
-
Product Insights
Chemotherapy Induced Oral Mucositis – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Oral Mucositis - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Oral Mucositis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Gouty Arthritis (Gout) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Drugs In Development, 2023’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2023’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...